Screening for lead poisoning: Who to test and when to act

Key takeaways

Screening for lead poisoning means testing blood before symptoms appear, because no blood lead level is safe in children.

Current AAP and CDC guidance favors risk-based screening, with universal testing for high-prevalence areas, Medicaid-enrolled children, and state mandates.

The CDC reference value is 3.5 µg/dL, lowered from 5 µg/dL on October 28, 2021.

A fingerstick only screens. Confirm every elevated capillary result with a venous draw before you act on it.

Confirmation timing scales with the number, from three months at 3.5 µg/dL down to 48 hours at 45 µg/dL.

Nearly 500,000 US children aged 1 to 5 have blood lead levels above the CDC’s reference value. Most show no symptoms at all. By the time a child looks unwell, the harm to a developing brain has usually already been done.

The screening for lead poisoning has to find which children you test, how you collect the sample, and how fast you confirm a high result all matter. Get any of it wrong and the chart says the screen was done while the exposure carries on.

No safe blood lead level means symptoms can’t guide you

There is no safe blood lead level in children. The American Academy of Pediatrics (AAP) and the CDC both hold that position. Even low-level exposure is linked to reduced IQ, attention problems, and behavioral difficulties that surface years later.

Blood lead level, or BLL, is measured in micrograms per deciliter. The CDC lowered its reference value for children from 5 µg/dL to 3.5 µg/dL on October 28, 2021.

That number is a population marker and flags the highest 2.5% of children by exposure, and any child at or above it needs follow-up.

Adults need testing too, though the picture differs. Occupational exposure, renovation work on pre-1978 housing, and hobbies like shooting, stained glass, and pottery all raise blood lead. In adults, the consequences are cardiovascular, renal, and reproductive, and they build quietly over years.

Who to screen: Risk assessment first, blood test second

Current AAP and CDC guidance favors targeted screening built on a risk assessment, rather than a blood test for every child. You ask the risk questions at well visits from 6 through 24 months, then annually from ages 3 to 6. A blood test follows when the answers point toward exposure.

Universal testing applies in high-prevalence areas, for children enrolled in Medicaid, and wherever a state mandates it. Medicaid is the widest of the three. Every enrolled child must be tested at 12 and 24 months. Any child aged 24 to 72 months with no record of a test needs one too.

The risk questions themselves are short. Ask about:

• Housing built before 1978, either at home or somewhere the child visits often
• A sibling or playmate with an elevated blood lead level
• A parent whose job or hobby involves lead
• Recent arrival from a country with a high lead burden
• Folk remedies, imported spices, cosmetics, or glazed pottery used in the home

These questions belong in the same part of the visit as the standardized developmental screen you already bill under 96110. Staff are asking structured questions there anyway, so one more block of them barely changes the flow. If your intake paperwork skips housing age, add it to the new patient questionnaire instead of leaving it to memory.

Does a clean risk assessment mean the child never needs a test? No. Risk changes when a family moves, a parent switches jobs, or a new caregiver enters the picture. That is why the questions repeat at every well visit rather than once.

For adults, targeted screening covers construction, battery manufacturing, smelting, firing ranges, and radiator repair. Pregnant patients with known occupational or residential exposure should be assessed as well.

Refugee and newly arrived children need two tests, not one

Two groups need testing whatever the questionnaire says. Refugee children under 16 are tested on arrival in the US. Children under 6 are then tested again three to six months after they settle into permanent housing.

That second test is the one that goes missing, because it often belongs to a different program than the pediatric chart. Practices running arrival visits on separate travel clinic software should set the repeat test as a recall there.

Universal or targeted: Your state usually decides

Your state health department, not the CDC, sets the rule you actually follow. High-prevalence states mandate a test at 12 and 24 months and take the questionnaire out of the decision. Lower-prevalence states leave the call to the risk assessment.

New York, for example, requires a blood lead test for every child at ages 1 and 2. It also requires one for any child aged 3 to 6 with no previous test. Policies differ enough that reading your own state’s rule is worth twenty minutes of somebody’s morning.

Symptoms arrive late, so sources tell you more

Lead exposure produces almost no early symptoms, which is why clinical presentation cannot drive testing decisions. Below 10 µg/dL, most children look completely well. A pediatric physical examination can be entirely normal in a child whose level already warrants action.

Symptoms that do appear are easy to blame on something else. Irritability, fatigue, abdominal pain, constipation, headache, and trouble concentrating all show up at higher levels. Encephalopathy, seizures, and coma sit at the severe end and count as a medical emergency.

Most children found through a screening program will be well below the symptomatic range. That is the whole point of screening, and it is also why sources tell you more than signs do.

Lead hits children’s brains and adults’ kidneys

Children carry the heavier burden, because a developing nervous system absorbs more and tolerates less.

The main effects are neurodevelopmental, including lowered IQ, weaker executive function, attention and behavior problems, and poorer school performance. At sufficient exposure, none of it reverses.

Adults show a different pattern. Chronic exposure is associated with hypertension, chronic kidney disease, peripheral neuropathy, and poor reproductive outcomes. Cognitive effects occur as well, but they need higher cumulative exposure.

The sources, though, barely change between the two groups:

• Lead-based paint and paint dust in pre-1978 housing, still the dominant pediatric source
• Lead service lines and plumbing fixtures, particularly in homes built before 1986
• Contaminated soil near former industrial sites, smelters, or heavily trafficked roads
• Occupational exposure in construction, battery recycling, radiator repair, and firearms
• Imported goods, including certain ceramics, spices, cosmetics, and folk remedies
• Shooting ranges, where ammunition primers and bullet impact put lead into the air

In a high-risk area, the environmental history belongs in every well-child visit, and it takes about ninety seconds to ask. Once it points toward exposure, the next decision is how you take the blood.

A fingerstick screens, a venous draw decides

The blood lead level test is the only tool that identifies lead exposure in a patient. You can collect the sample two ways, and the choice determines what you are allowed to do with the number that comes back.

How to keep a fingerstick from lying to you

Capillary collection is quicker, cheaper, and far kinder to a one-year-old, which is why most pediatric offices start there. It also picks up lead sitting on the skin, and that is the usual cause of a falsely high result. ARUP Consult and state programs alike treat an elevated capillary value as a screen, never a diagnosis.

Four steps keep the sample honest:

1. Wash and dry the hands. Soap and warm water, then a full dry. An alcohol wipe on its own will not lift lead dust.
2. Check your supplies. Lancets, capillary tubes, and gloves all need to be lead-free and powder-free.
3. Wipe away the first drop. Start collecting from the second drop onward.
4. Let the blood flow. Squeezing the finger dilutes the sample with tissue fluid and skews the reading.

Venous blood is the confirmatory and follow-up method. It gives a more accurate result, and it is required whenever a capillary value reaches the reference value. The draw is coded separately from the lead assay, under 36415.

What a home test kit can and cannot tell a parent

Over-the-counter lead kits test surfaces, not people. They check paint, dust, and water, and they say nothing about what is in a child’s blood.

Parents sometimes arrive believing a clear kit rules out exposure. Only a blood test answers that question, and it is worth saying so directly in the room.

What the number means, and how fast you must confirm it

A blood lead result carries two separate decisions. First, is the level elevated? Second, how quickly do you need a venous sample to confirm it?

The reference value answers the first question. The confirmation schedule answers the second, and it tightens sharply as the number climbs.

That third column is the one that changes your afternoon. A capillary result of 46 µg/dL needs a venous draw inside two days, and your recall system has to know it.

Reference values do get revised as population data accumulates, so check the current published guidance when you are making the decision.

Your state, not the CDC, sets the reporting rules

Most US states require providers to report blood lead results to the state health department, elevated or not. New York, for example, requires reporting of every result for children under 18. States with universal screening laws usually apply the same rule to every child tested.

What varies between states is worth checking line by line:

• Which age groups the requirement covers
• The level that triggers a report, where there is a threshold at all
• The deadline, which can be same-day for critically high results
• Whether the laboratory’s report satisfies the obligation, or the ordering provider must file separately

That last one causes the most trouble. Teams often assume the lab has it covered, and in several states that assumption leaves the practice out of compliance.

Reporting also sends identifiable results into a public health registry, which your privacy documentation needs to cover. Practices already working through HIPAA compliance can slot lead reporting into the permitted-disclosure logic they built for communicable disease reporting. Keeping patient data security controls consistent across both saves writing the policy twice.

After a confirmed result: five steps in order

Reporting is one obligation, and treating the child is the other. Once a venous BLL sits at or above the reference value, the pathway looks the same almost everywhere. The order matters more than the speed of any single step.

1. Find the source. Work through housing age and condition, water supply, parental occupation, and any imported goods in the home.
2. Refer for remediation. Notify local public health or environmental health, who can inspect the home and push remediation along. The EPA’s lead program lists referral routes for owners and renters.
3. Counsel on nutrition. Adequate calcium, iron, and vitamin C reduce how much lead the gut absorbs. It helps, but it is no substitute for treatment at clinically significant levels.
4. Set the rescreening date. Frequency depends on the starting level, the child’s age, and whether the source has been dealt with.
5. Refer to case management. At 10 µg/dL and above, a lead case manager or public health nurse coordinates inspection, family education, and monitoring. Patient care management workflows that automate the reminders keep those rescreening visits from slipping.

Chelation starts at 45 µg/dL, and not before

Chelation is indicated when a child’s blood lead level reaches 45 µg/dL. Mayo Clinic guidance and current AAP recommendations agree on that threshold. Below it, the drugs carry more risk than benefit.

DMSA, also called succimer, is the first-line oral agent in children. EDTA is held back for very high levels, or for cases where DMSA cannot be used. Either route needs specialist management, plus close monitoring of renal function and blood counts.

Chelation also does nothing about the house. Removing the child from the source is still the step that decides the long-term outcome.

Where screening programs lose children to follow-up

The clinical protocol above is well documented. The operations around it are where children quietly drop out of the program, and four failure points account for most of it:

• The 24-month visit that never happened. The first test gets done, the family moves or reschedules, and nobody notices the second one is missing.
• The capillary result nobody chased. An elevated fingerstick lands in the chart, the venous draw is never booked, and the file still looks complete.
• The risk assessment that ran once. A questionnaire answered at 12 months says very little about the same family at 3 years.
• The report nobody owned. Everyone assumes the laboratory filed it, so nobody checks.

Run this checklist before the sample leaves the room

• Hands washed and dried, not just wiped
• The order names a blood lead level, not a general heavy metals panel
• The collection method, capillary or venous, is written in the note
• The result has a named owner for follow-up, not just a place in the chart
• The next test date is on the recall list before the family leaves
• Your state’s reporting route is written somewhere the whole team can see it

None of that is clinically hard. It is scheduling, naming an owner, and writing things down.

Recall is the load-bearing piece. The 12-month appointment tends to book itself, since families come in for vaccines anyway. The 24-month lead test only happens if something remembers it, which is what patient recall software is built to do.

Size changes how you run it. In a solo practice, one person can hold the list in their head, and it usually works. A group practice cannot lean on that, because no single clinician sees every 12-month visit. The tracking has to live in the system rather than in someone’s memory.

Then check your own work. A quarterly chart audit against the 24-month cohort shows you the completion rate you have, rather than the one you assume. Pair it with the immunization record form review, since the same children and the same visits are involved.

How Pabau keeps a lead screening program on schedule

Every failure point above is a tracking problem rather than a clinical one. Practice management software like Pabau holds those pieces in one place, so the program stops depending on who is in the building that week.

Automated recall workflows flag each patient at 12 and 24 months, so no child ages past the window without a prompt. When a capillary result comes back elevated, the same workflow books the confirmatory venous draw instead of leaving it on a sticky note.

Digital intake forms carry the lead risk questions into the pre-visit paperwork, and the answers land in the clinical record on their own. Nobody retypes a questionnaire while a toddler is in the room.

Client records then hold the capillary value and the venous value with timestamps. That is exactly what a case manager or a state registry asks for. Practices running primary care on GP clinic software get the recall list, the documentation, and the reporting trail from one system. Nothing has to be reconciled by hand at the end of the month.

Keep every lead screening recall on schedule

Pabau flags children due for testing at 12 and 24 months, then books the confirmatory venous draw after an elevated fingerstick. Both results stay in one record for reporting, so your team stops tracking it by hand.

Book a demo

Conclusion

Lead screening rewards practices that are boring about it. The clinical decisions are few and well defined. Almost everything that goes wrong is a date nobody tracked or a result nobody owned.

So pick two numbers and hold on to them. At 3.5 µg/dL, the result needs follow-up rather than reassurance. Reach 45 µg/dL and the child needs a specialist, plus a venous draw inside 48 hours. Everything between those points is process, and process can be fixed.

If your screening program runs on one person remembering, it holds until that person takes a vacation. Book a demo to see how Pabau tracks lead screening recalls, confirmatory draws, and state reporting in one place.

Continue your research

Want the lead risk questions to fill themselves in? Medical forms at your practice shows how to move intake paperwork out of the waiting room.

Losing rescreening appointments to no-shows? How to improve patient no-show rate covers the reminder timing that keeps families coming back.

Need a developmental screen alongside the lead result? Denver developmental screening test gives you a structured way to track milestones.

Building out your well-child documentation? Pediatric review template covers the history and exam findings worth capturing at every visit.

Want families booking their own follow-up visits? Patient portal software explains how self-service booking takes pressure off the front desk.

Frequently asked questions